Sagimet Biosciences grants RSUs to executives post-IPO; CEO Happel receives 624,910 units

Sagimet Biosciences Inc.

Board approved RSU grants: CEO David Happel (624,910), Eduardo Martins (89,570), George Kemble (150,750).
RSUs vest 25% on first anniversary of IPO closing, remainder over three years, subject to continued service.
Compensation Committee engaged Compensia to align executive compensation with public-company peers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.